HeartBeam aligned with the FDA on a 510k pathway, plans a pivotal study beginning in 2027, reported Q3 2026 operating cash use of $2.6 million, and had pro forma cash of approximately $10.1 million.
BEAT · HeartBeam, Inc. · Documents
$0.28
-0.03 (-8.90%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan assumptions and expected cash burn rate, the Company believes that the existing cash is insufficient to fund operations for the next twelve months following the issuance of these financial statements. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 12, 2026
Market Cap
$19.56M
Shares
63.31M
Volume · Nov 20
403.48K
Avg daily vol (3M)
7.39M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2026
Nov 12
Earnings call
FDA pathway supports accelerated pivotal study plan
Nov 12
Quarterly report
10-Q
FY2026 Q3, ended Sep 30
FDA grants heart attack assessment breakthrough designation
HeartBeam, Inc. received FDA Breakthrough Device Designation for heart attack assessment on October 5, 2026. ALIGN-ACS showed 81.8% specificity versus 71.4% for 12-lead ECG; Nasdaq compliance is due by December 28, 2026, and cash is insufficient for twelve months.
Net loss $3.01M
Diluted EPS -$0.05
Aug 14
Aug 13
Aug 13
Quarterly report
10-Q
FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2
AI summary on its way
Net loss $5.04M
Diluted EPS -$0.10
Aug 6
Current report
8-K/A
Events of Jun 18
Director or officer change, or executive pay
AI summary on its way
Aug 3
Jul 2
Jun 25
Jun 24
Current report
8-K
Events of Jun 18
Director or officer change, or executive pay, Other events
AI summary on its way
Jun 22
Current report
8-K
Events of Jun 15
Director or officer change, or executive pay
AI summary on its way
Jun 18
Jun 5
May 13
May 13
Quarterly report
10-Q
FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1
AI summary on its way
Net loss $4.7M
Diluted EPS -$0.12
Apr 16
Current report
8-K
Events of Apr 14
Entered into a material agreement, Other events
AI summary on its way
Mar 13
Mar 12
Mar 12
Annual report
10-K
FY2025, ended Dec 31
Annual report for FY2025
AI summary on its way
Net loss $21.02M
Diluted EPS -$0.62
Feb 9
2025
Nov 21
Current report
8-K
Events of Nov 20
Other events
Nov 13
Quarterly report
10-Q
FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Net loss $5.26M
Diluted EPS -$0.15
Sep 30
Earnings call
Q3 2025 earnings call
Aug 13
Quarterly report
10-Q
FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Net loss $4.97M
Diluted EPS -$0.15
Jul 16
Current report
8-K
Events of Jul 11
Shareholder vote results
Jun 30
Earnings call
Q2 2025 earnings call
May 29
Proxy statement
DEF 14A
Proxy statement
May 19
Proxy statement
PRE 14A
Proxy statement
May 13
Quarterly report
10-Q
FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Net loss $5.48M
Diluted EPS -$0.18
May 5
Current report
8-K
Director or officer change, or executive pay, Regulation FD disclosure
Apr 25
Current report
8-K
Events of Apr 21
Change of auditor
Mar 31
Earnings call
Q1 2025 earnings call
Mar 13
Annual report
10-K
FY2024, ended Dec 31
Annual report for FY2024
Net loss $19.45M
Diluted EPS -$0.73
Feb 26
Current report
8-K
Events of Feb 21
Other events
Feb 18
Current report
8-K
Events of Feb 12
Entered into a material agreement, Other events
2024
Dec 31
Earnings call
Q4 2024 earnings call
Nov 7
Quarterly report
10-Q
FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Net loss $4.98M
Diluted EPS -$0.19
Oct 23
Current report
8-K
Events of Oct 17
Director or officer change, or executive pay, Regulation FD disclosure
Sep 30
Earnings call
Q3 2024 earnings call
Sep 10
Current report
8-K
Events of Sep 9
Director or officer change, or executive pay
Aug 14
Quarterly report
10-Q
FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Net loss $4.96M
Diluted EPS -$0.19
Jun 30
Earnings call
Q2 2024 earnings call
Jun 18
Current report
8-K
Events of Jun 12
Shareholder vote results
May 9
Quarterly report
10-Q
FY2024 Q1, ended Mar 31
Quarterly report for FY2024 Q1
Net loss $4.61M
Diluted EPS -$0.17
May 2
Current report
8-K
Entered into a material agreement, Ended a material agreement
Apr 30
Proxy statement
DEF 14A
Proxy statement
Apr 19
Proxy statement
PRE 14A
Proxy statement
Mar 31
Earnings call
Q1 2024 earnings call
Mar 20
Annual report
10-K
FY2023, ended Dec 31
Annual report for FY2023
Net loss $14.64M
Diluted EPS -$0.72
Feb 5
Current report
8-K
Events of Feb 1
Director or officer change, or executive pay
Showing 1–50 of 108 documents